[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad de Granada\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":629},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,50,89,122,155,178,207,234,262,295,325,346,372,399,429,458,484,506,539,559,580,607],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100617210","time-restricted-eating-as-a-potential-strategy-to-promote-weight-loss-maintenance-in-patients-with-obesity-100617210",false,"NCT07315659","Time-Restricted Eating as a Potential Strategy to Promote Weight Loss Maintenance in Patients With Obesity","Time-Restricted Eating as a Potential Strategy to Promote Weight Loss Maintenance in Patients With Obesity (REGANE)","REGANE","Inclusion Criteria:\n\n* Have a body mass index of 30-45 kg\u002Fm2.\n* Have safety laboratory test results (general biochemistry and complete blood count) within the normal reference range or with abnormalities considered clinically insignificant by the medical research team and that do not require the initiation of drug treatment.\n* Have sufficient venous access for the blood sampling required by the procedures described in this protocol, and not have a phobia of needles or blood.\n* Maintain a usual intake window of 11 hours or longer at least 5 days a week and have a response rate greater than 85% during the self-recording carried out during the screening process.\n* Willingness and ability to consume all foods provided during the outcome assessment and dietary intervention.\n* Being able to understand and undergo the procedures that are part of the study, in the opinion of the research team.\n* Availability to participate in the study.\n* Be willing to complete the study regardless of the group to which they are assigned.\n\nExclusion Criteria:\n\n* Having received a diagnosis or presenting signs or symptoms that, in the opinion of the research team, could contraindicate TRE intervention or any of the procedures included in the study.\n* Having been diagnosed with or having a history of metabolic (including a diagnosis of any type of diabetes mellitus), hematological, pulmonary, cardiovascular, gastrointestinal, neurological, immune, hepatic, renal, urological or psychiatric diseases that could interfere with the study results or compliance with the protocol.\n* Having undergone any surgical procedure that, in the opinion of the research team, could alter energy metabolism or digestive function during the course of the study.\n* Taking drugs or supplements that are likely to alter body weight or appetite.\n* Have experienced weight loss of more than 10% in the last two years, or more than 5% in the last 6 months, unless all the weight lost has been regained.\n* Follow unconventional eating patterns, such as vegan or fasting diets, or be unable to tolerate the foods provided during the study.\n* Being pregnant or planning to become pregnant within the next two years.\n* Being in the postpartum phase (within 12 months of giving birth) or breastfeeding.\n* Being in the perimenopausal stage, defined as meeting the criteria of irregular menstrual cycles, hormonal changes indicative of perimenopause, or the presence of menopausal symptoms.\n* Participating in a nutritional intervention or treatment or having done so during the previous 3 months.\n* Having been diagnosed with or showing signs or risk factors for the development of an eating disorder.\n* Experiencing frequent interruptions in the sleep-wake cycle.\n* Having clinically significant gastric emptying abnormalities, a current diagnosis of any form of diabetes, blood pressure greater than 160\u002F90 mm Hg, or heart rate below 50 or above 100 beats per minute (sitting), with or without stable doses of antihypertensive medication.\n* Have an active or untreated malignant disease or be in remission from a clinically significant malignant disease for less than five years prior to the time of evaluation.\n* Having a history of drug or alcohol abuse or testing positive for drugs, unless due to medication prescribed by a healthcare professional.\n* Smoking, vaping, or regular use of tobacco products, unless there have been periods of at least 24 consecutive hours without consumption during the last 4 weeks.\n* Regular consumption of caffeine in excess of the equivalent of 3 espressos per day (225 mg\u002Fday).\n* Being a direct relative or cohabitant of research team personnel.\n* Any other condition that, in the opinion of the research team, makes participation in the study inadvisable.","ALL","18 Years","70 Years",{"count":21,"type":22},212,"ESTIMATED","INTERVENTIONAL",[25],"NA","While body weight reduction can be achieved through various interventions in people living with obesity, most patients regain a substantial proportion of the lost weight within the following months. There is a lack of effective interventions to prevent this regain, making weight regain one of the most pressing challenges in obesity management. The goal of this clinical trial is to determine whether adhering to time-restricted eating (TRE; a form of intermittent fasting) during and after a dietary weight loss intervention, promotes weight maintenance to a greater extent than consuming all daily meals within 11 hours or more. Additionally, the study will address other questions, such as whether TRE improves body composition, insulin sensitivity, and cardiometabolic risk factors; whether the TRE intervention produces effects on different components of energy balance or related behaviors; and whether prior exposure to the TRE intervention influences eating window duration and weight change over the subsequent 24 months.\n\nThe study will compare participants who concentrate all their food intake within 8 hours or less with those who consume all their daily meals within 11 hours or more. All participants will follow a calorie-restricted diet designed to induce an 8-10% weight loss over 12-16 weeks and will be followed for several months after the weight loss intervention.",[28],"Obesity",[28,30,31,32,33,34,35,36],"Calorie restriction","Intermittent Fasting","Weight loss","Weight loss maintenance","Weight regain","Time-restricted eating","Diet","RECRUITING","2026-05-09",{"date":40,"type":41},"2026-05-12","ACTUAL",{"date":43,"type":41},"2025-12-18",{"date":45,"type":22},"2030-06",{"name":47,"class":48},"Universidad de Granada","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":49},"100611434","efficacy-of-a-multimodal-physiotherapy-program-and-mobile-app-guided-meditation-in-adults-with-frequent-or-chronic-tension-type-headache-100611434","NCT07240532","Efficacy of a Multimodal Physiotherapy Program and Mobile-App Guided Meditation in Adults With Frequent or Chronic Tension-Type Headache","Efficacy of a Multimodal Physiotherapy Program and Mobile-App Guided Meditation in Adults With Frequent or Chronic Tension-Type Headache: A Randomized Clinical Trial","JBE-CEF","Inclusion Criteria:\n\n* Diagnosis of frequent or chronic tension-type headache (TTH) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria.\n* Ability to understand and communicate in Spanish sufficiently to follow instructions and complete questionnaires.\n* Willingness to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Diagnosis of migraine or other primary or secondary headache disorders.\n* Presence of red flags for manual therapy, including bone pathology, inflammatory disease, malignancy, neurological disorders, vestibular dysfunction, or skin infection in the cervical area.\n* Fibromyalgia, pregnancy, or lactation.\n* Use of pacemakers or implantable defibrillators.\n* Recent medication adjustments, particularly involving psychotropic or chronic pain drugs.\n* Severe psychiatric disorders (major depressive episode, bipolar disorder, schizophrenia, or other psychotic conditions).\n* Previous physical treatment targeting the cranio-cervical region (manual therapy, dry needling, anesthetic blocks) within the last six months.\n* Regular practice of meditation or mindfulness during the last six months.\n* Participation in another clinical trial during the study period.","45 Years",{"count":60,"type":22},78,[25],"The goal of this clinical trial is to evaluate whether a multimodal physiotherapy program and guided meditation using a mobile app can help reduce headache pain and improve quality of life in adults with frequent or chronic tension-type headache. The study analyzes the effects of physical and psychological interventions applied both separately and in combination, so that the combined treatment addresses tension-type headache as a multifactorial condition influenced by biopsychophysiological factors, integrating physical and psychological strategies to improve participants' overall well-being.\n\nThe main questions it aims to answer are:\n\n* Does multimodal physiotherapy lower the intensity and frequency of headaches?\n* Does guided meditation through a mobile app help reduce stress and improve emotional well-being?\n* Are the combined effects of physiotherapy and meditation greater than either intervention alone?\n\nThe study will compare:\n\n* A group receiving multimodal physiotherapy sessions once a week for four weeks,\n* A group practicing guided meditation with a mobile app for about 5 to 7 minutes daily,\n* A group combining both physiotherapy and meditation.\n\nParticipants will:\n\n* Attend clinical sessions or use the meditation app depending on group assignment,\n* Complete short questionnaires about pain, stress, sleep, and daily functioning,\n* Record headache episodes in a structured diary during the study period.",[64,65,66],"Tension-Type Headache","Chronic Tension-type Headache","Frequent Episodic Tension-Type Headache",[64,68,69,70,71,72,73,74,75,76,77,78,79],"Chronic Tension-Type Headache","Multimodal Physiotherapy","Manual Therapy","Dry Needling","Mindfulness","Guided Meditation","Mobile Application","Non-Pharmacological Treatment","Randomized Controlled Trial","Biopsychophysiological Approach;","Pain Management","Headache Disability","NOT_YET_RECRUITING","2026-05-05",{"date":83,"type":41},"2026-05-11",{"date":85,"type":22},"2026-07",{"date":87,"type":22},"2027-06",{"name":47,"class":48},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":97,"minAge":18,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":49},"100555908","preventing-breast-cancer-therapy-related-cardiovascular-toxicity-with-a-daily-adapted-program-with-mhealth-support-100555908","NCT06518200","Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support","ATOPE-PRO: Effects on the Prevention of Breast Cancer Therapy-related Cardiovascular Toxicity of a Daily-adapted and Individualized Program With Support From a Mobile Application","ATOPE-PRO","Inclusion Criteria:\n\n* Recently diagnosed with stage I-III breast cancer\n* Treatments predisposing to cardiotoxicity (anthracyclines, targeted therapies, radiotherapy)\n* Signed informed consent form\n* Medical authorisation to participate\n* Smartphone user level\n\nExclusion Criteria:\n\n* Patient underwent previous cancer treatments.\n* Patients were previously diagnosed with cancer\n* Pregnant patients. Patients performing other type of therapeutic exercise at diagnosis time with an intake \\>or = to 150 moderate-intensity or 75 min of vigorous-intensity a day\n* Therapeutic exercise practice not recommended because psychiatric or cognitive disorders or cute or chronic condition that prevents exercise (advanced lung disease, oxygen requirement, stenosis \\>70%, metastasis etc.).","FEMALE","65 Years",{"count":100,"type":22},102,[25],"ATOPE-PRO, was developed with the intention of consolidating the integration of an innovative system for the prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT) in the continuum care of women with breast cancer in health services. It is a step further towards personalized medicine by optimizing the already available tools and integrating artificial intelligence. Breast cancer survival increases every year, a situation that poses new challenges for health professionals. The European Society for Medical Oncology, a reference in Europe, has just highlighted the need to anticipate to and prevent sequelae derived from the disease and its treatments. This, in addition to having a positive impact on improving the quality of life of people suffering from this disease, would mean a reduction in the risk of recurrence, the appearance of other tumors and other diseases, and death from cancer or other causes, which have a personal impact and represent an overload of the healthcare system. To this end, ATOPE- PRO aims to optimize and refine tools already developed in the previous project (ATOPE, Pl18\u002F01840), integrating artificial intelligence to help identify CTR-CVT, risk profiles, and effective and safe doses (at a clinical level) early on, implementing the program in a longer term, and transferring the results to the social sector (social level). The project has 4 stages: Phase 0 or start-up (to make improvements and analyse usability); Phase 1 for piloting and optimization; Phase 2, to verify efficacy (randomized controlled clinical trial) and Phase 3, in which a deep analysis will be performed and future projects will be conceived.",[104],"Breast Cancer Female",[106,107,108,109,110,111,112,113],"Breast Neoplasms","Cancer therapy-related cardiovascular toxicity","Physical Exercise","Prevention","Quality of life","Rehabilitation","Telemedicine","Health related lifestyle","2026-04-30",{"date":116,"type":41},"2026-05-06",{"date":118,"type":22},"2026-09-01",{"date":120,"type":22},"2028-12-31",{"name":47,"class":48},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":49},"100594654","virtual-exercise-training-and-its-impact-on-bone-compartments-in-adult-survivors-of-childhood-cancer-100594654","NCT07022262","Virtual Exercise Training and Its Impact on Bone Compartments in Adult Survivors of Childhood Cancer","3D-BONE: Virtual Exercise Training and Its Impact on Cortical and Trabecular Bone Compartments in Adult Survivors of Childhood Cancer: a Peripheral Quantitative Computed Tomography (pQCT) Study","3D-BONE","Inclusion Criteria:\n\n* Prior diagnosis of pediatric cancer and history of receiving treatment (radiation therapy and\u002For chemotherapy).\n* 18-55 years of age at recruitment\n\nExclusion Criteria:\n\n* Participation in another research study simultaneously.\n* Not currently receiving cancer treatment.\n* Previous diagnosed anorexia\u002Fbulimia, known pregnancy, known alcohol or drug abuse.\n* Requiring chronic oral glucocorticoid therapy.\n* Having an injury that may affect daily life activities and can be aggravated by exercise.","55 Years",{"count":132,"type":22},116,[25],"Childhood cancer is a rare disease but a significant cause of death in children and adolescents. The incidence of childhood cancer is 1case per 300 cases of adult cancer, but surviving to it has important sequels. Endocrine dysfunction represents one of the most common issues in paediatric cancer survivors and impairs bone mineral density later in life. Some forms of exercise have been recommended to preserve bone health in healthy adults; however, its effect has not been properly studied yet in adult survivors of paediatric cancer using cutting-edge technologies, such as peripheral quantitative computed tomography (pQCT). As general aim, the 3D-BONE study will assess for the first time the effect of a live and online exercise programme on bone parameters and bone metabolism in adult survivors of paediatric cancer. This multicenter randomized controlled trial will be performed in three Andalusian provinces (Granada, Cordoba and Almeria). A minimum of 116 adult survivors of paediatric cancer aged 18 to 55 years will be recruited following the inclusion and exclusion criteria. They will be randomized (based on sex and age) into an INTERVENTION (n=58) or CONTROL group (n=58). The intervention group will receive a 6-month live and online exercise program based on progressive resistance and impact loading training that will be delivered by qualified professionals using a telehealth mobile app (3D-BONE app). Moreover, behaviour change techniques will be implemented in order to increase motivation and adherence to the program. This group will also receive diet counselling on calcium and vitamin so the difference between the groups is the exercise programme. Participants will be assessed before and after the intervention at the facilities of the Sport and Health University Research Institute (iMUDS) of the University of Granada. An in-depth analysis of bone parameters will be carried out using cutting-edge technologies, such as the pQCT (to analyse cortical and trabecular bone in 3 dimensions), dual-energy X-ray absorptiometry (DXA), hip and lumbar spine geometry outcomes. Moreover, a complete blood count will be obtained and markers of bone metabolism will be measured (B-CTX, PINP), including novel markers such as sclerostin and irisin which have recently been linked to human bone. Data will also be collected in anthropometry and body composition to obtain cardiovascular risk factors, sarcopenia and physiologic frailty risk factors, mental health, health-related quality of life and objective measures of physical activity and fitness. This will ensure obtaining novel, precise and strong data in this population.",[136],"Cancer Survivors",[138,139,140,141,142,143,144,145,146,147],"cancer survivors","childhood cancer","exercise","bone health","physical fitness","sarcopenia","physiological frailty","mental health","health-related quality of life","pQCT","2026-04-29",{"date":116,"type":41},{"date":151,"type":22},"2026-05",{"date":153,"type":22},"2028-08",{"name":47,"class":48},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":162,"enrollmentInfo":163,"targetDuration":165,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":49},"100607496","multi-scale-spatio-temporal-analysis-of-research-data-100607496","NCT07189312","Multi-scale Spatio-Temporal Analysis of Research Data","MuSTARD","Inclusion Criteria:\n\n* Diagnosis for colorectal cancer\n* Patients with cancer planned surgery\n* Absence of instability microsatellites\n* Absence of any other associated disease that can affect the cancer pathology\n\nExclusion Criteria:\n\n* Patients who need an urgent surgery","90 Years",{"count":164,"type":22},15,"3 Months","OBSERVATIONAL","MuSTARD is a singular project in the sense that investigators will develop a computational framework that is conceived as a common solution for disparate applications. This framework responds to a common need: the derivation of multi-scale spatio-temporal (ST) models equipped with statistical inference capabilities. Since the sequencing of the human genome, a significant portion of clinical research has shifted to the study of precision medicine (PM), resulting in numerous breakthroughs in both non-communicable and infectious diseases. PM refers to disease treatment and prevention that considers variability in genes, environment, and lifestyle for each person. Main drivers of PM are the omics technologies . Omics data is obtained from new high-throughput instruments that generate massive volumes of data. It is also notoriously complex data to analyze. In the last years, new separation technology has allowed us to measure omics data at single-cell resolution, creating a new (and even more complex) type of data generally referred to as single-cell omics. This allow us to study the spatial distribution of omics in a sample. Spatial and single cell omics represents one of the most powerful approaches today to understand cancer propagation in both time and space. Spatial omics. Unfortunately, there are no computational tools that can readily combine the nature of this new type of data with powerful statistical inference. Furthermore, spatially resolved omics experiments with repeated measures is another form of complex ST data. MuSTARD will provide a new computational framework that can handle ST omics to understand colorectal cancer propagation in both time and space, and leverage it in a new clinical study of reduced sample size (15 patients). The MuSTARD computational framework applied to ST omics will be made available for the general community in the form of open software.",[169],"Colorectal Cancer","2026-04-27",{"date":172,"type":41},"2026-04-28",{"date":174,"type":41},"2025-02-02",{"date":176,"type":22},"2026-12-02",{"name":47,"class":48},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":186,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":49},"100633610","tujugling-comparing-two-juggling-learning-methods-in-college-students-100633610","NCT07528924","TuJugling: Comparing Two Juggling Learning Methods in College Students","TuJugling: a Cluster-randomized Cross-over Trial Comparing Two Juggling Learning Methods in College Students","TuJugling","Inclusion Criteria:\n\n* Enrolled in the Motor Games course.\n* Aged ≥18 years and able to understand and provide informed consent.\n* Provide explicit agreement to participate in the study assessments.\n\nExclusion Criteria:\n\n* Injury or medical condition that prevents safe participation in juggling, based on self-report prior to baseline assessment.\n* Uncorrected or insufficiently corrected visual impairment that prevents seeing and tracking the balls during practice and assessments.",true,{"count":188,"type":22},200,[25],"This study will compare two ways of learning juggling in university students during a regular practical course: (A) juggling based on throwing the balls in the air and (B) juggling based on bouncing the balls off the floor. The study will also examine whether the order in which students learn these methods (A then B vs. B then A) influences how their performance improves over time.\n\nStudents will follow two 4-week practice periods separated by a 1-week break, and juggling performance will be assessed at three time points (baseline, after period 1, and after period 2). Performance will be scored from video recordings using anonymized study identifiers. Questionnaires about mood and flow experience will be collected at each assessment, and handgrip strength and brief computerized cognitive tasks will be assessed at baseline and the final evaluation in an exploratory manner.\n\nThe main comparison of training methods will focus on results after the first period to reduce the influence of prior practice, while results after the second period will be used to describe learning trajectories, order effects, and transfer to different execution conditions.",[192,193],"Motor Skill Learning","Juggling Performance",[195,196,197,198],"Juggling","Motor learning","Educational intervention","Motor performance","2026-04-07",{"date":201,"type":41},"2026-04-14",{"date":203,"type":41},"2026-03-01",{"date":205,"type":22},"2026-07-01",{"name":47,"class":48},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":186,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":231,"leadSponsor":233,"locationsCount":49},"100631209","saffron-extract-supplementation-and-sleep-quality-in-middle-aged-adults-100631209","NCT07497698","Saffron Extract Supplementation and Sleep Quality in Middle-Aged Adults","Effects of Daily Saffron Extract Supplementation on Sleep Quality in Middle-Aged Adults: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial","SAFFRON-SLEEP","Inclusion Criteria:\n\n* Age 18-65 years\n* Mild-to-moderate sleep disturbances\n* BMI between 18 and 35 kg\u002Fm²\n* Not receiving active pharmacological or psychological treatment for sleep disorders\n* Willingness to comply with study procedures\n\nExclusion Criteria:\n\n* Severe neurological, psychiatric, or cardiovascular disorders\n* Diagnosed with obstructive sleep apnea, treated with CPAP\n* Night shift workers\n* Use of medications or supplements affecting sleep\n* Recreational drug use\n* Pregnancy or breastfeeding\n* Uncontrolled medical conditions",{"count":216,"type":22},80,[25],"This randomized, triple-blind, placebo-controlled clinical trial aims to evaluate the effects of daily saffron extract supplementation (30 mg\u002Fday) for six weeks on objective and subjective sleep quality in middle-aged adults with mild-to-moderate sleep disturbances. Secondary outcomes include heart rate variability, cognitive processing speed, emotional state, perceived health status, and biochemical stress markers.",[220],"Sleep",[222,223,224,225,226,227],"Saffron extract","Sleep quality","Insomnia","Actigraphy","Nutraceutical","Randomized clinical trial",{"date":229,"type":41},"2026-04-13",{"date":203,"type":41},{"date":232,"type":22},"2027-06-01",{"name":47,"class":48},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":250,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":49},"100629490","comparison-of-bone-patellar-tendon-bone-and-patellar-tendon-bone-grafts-in-acl-reconstruction-100629490","NCT07475351","Comparison of Bone-patellar Tendon-bone and Patellar Tendon-bone Grafts in ACL Reconstruction","Comparison of Morbidity and Functional Outcomes After Anterior Cruciate Ligament Reconstruction With Bone-Tendon-Bone Graft Versus Patellar Tendon Graft Without Patellar Bone Plug in Competitive Athletes","Inclusion Criteria:\n\n* Time for injury to surgery of less than six months.\n* Active athletes (federated or recreational)\n* Patellar tendon length \\> 42mm measured by MRI.\n* Age between 12 and 40 years old\n* Genders eligible for Study: both\n\nExclusion Criteria:\n\n* Previous surgery or history of ligamentous knee injuries.\n* Concomitant knee ligament injury\n* Major meniscal injury (more than 50% of the lateral or medial meniscus)\n* Chondral injury greater than Outerbridge Grade I-II","12 Years","40 Years",{"count":244,"type":22},110,[25],"The purpose of this randomized study is to compare donor site morbidity and clinical and functional outcomes of both surgery techniques (bone-patellar tendon-bone (BPTB) graft versus bone-patellar tendon without patellar bone plug (PT) graft) for anterior cruciate ligament reconstruction (ACLR) in athletes. The main questions it aims to answer are:\n\n* Does PT graft reduce donor site morbidity compared to the standard BPTB graft?\n* Does PT technique provide clinical and functional results comparable to the BPTB technique? Researchers will compare the incidence of complications and clinical and functional outcomes between the BPTB and PT grafts groups.\n\nPatients will:\n\n* Undergo ACLR surgical intervention using one of the two assigned techniques (BPTB or PT)\n* Follow a two-year assessment program, including visits at three, eight, 12 and 24 months after surgery.",[248,249],"Anterior Cruciate Ligament (ACL) Reconstruction","Anterior Cruciate Ligament Injury",[251,252,253],"ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION","BONE PATELLAR TENDON BONE","PATELLAR TENDON","2026-03-18",{"date":256,"type":41},"2026-03-23",{"date":258,"type":41},"2026-01-01",{"date":260,"type":22},"2028-03",{"name":47,"class":48},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":186,"sex":17,"minAge":270,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":294},"100628720","phase-2-behavioural-intervention-to-decrease-exposure-to-emerging-chemical-pollutants-100628720","NCT07465315","Behavioural Intervention to Decrease Exposure to Emerging Chemical Pollutants","Effectiveness of a Behavioural Intervention to Decrease Exposure to Emerging Chemical Pollutants Compared to Standard Lifestyle Recommendations Among Adults in Spain (INPOL): a 3-month Multicentre, Parallel-group, Superiority Randomized Controlled Trial","INPOL","Inclusion Criteria for the Screening phase:\n\n* Not planning to change residence within one year after recruitment\n* Spanish fluency\n* Living independently in the community\n* WhatsApp user\n* Age 30-60 years\n* Providing signed informed consent\n\nExclusion Criteria for the Screening phase:\n\n* Unable to provide any of the required biological samples\n* Suffering any chronic condition that substantially hinders adherence to the trial protocol and\u002For affects pollutant analyses\n* Inability to understand the informed consent, questionnaires, or intervention\n* Already participating in another intervention trial at the time of recruitment\n* Pregnancy or lactation\n* Inability to communicate with the research team and\u002For to attend the follow-up visits\n\nInclusion Criteria for the Intervention Phase:\n\n* Not planning to change residence within one year after recruitment\n* Spanish fluency\n* Living independently in the community\n* WhatsApp user\n* Age 30-60 years\n* Providing signed informed consent\n* Participant of the Screening phase\n\nExclusion Criteria for the Intervention Phase:\n\n* Unable to provide any of the required biological samples\n* Suffering from any chronic condition that substantially hinders adherence to the trial protocol and\u002For affects pollutant analyses\n* Inability to understand the informed consent, questionnaires, or intervention\n* Already participating in another intervention trial at the time of recruitment\n* Pregnancy or lactation\n* Inability to communicate with the research team and\u002For attend follow-up visits","30 Years","60 Years",{"count":273,"type":22},740,[275,276],"PHASE2","PHASE3","The purpose of this study is to evaluate the effectiveness of a behavioural intervention designed to reduce exposure to environmental chemical pollutants among adults in Spain.",[279],"Environmental Exposure",[279,281,282,283,284,285,286],"Biological Monitoring","Biomarkers","Urine","Hair","Environmental Pollutants","Healthy Lifestyle","2026-03-12",{"date":289,"type":41},"2026-03-16",{"date":151,"type":22},{"date":292,"type":22},"2027-02",{"name":47,"class":48},5,{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":49},"100622893","promoting-safe-medication-practices-in-the-classroom-100622893","NCT07389538","Promoting Safe Medication Practices in the Classroom","Promoting Safe Medication Practices in the Classroom: Medicación Con-Ciencia","MedConCiencia","Inclusion Criteria:\n\n* Inclusion criteria will include being a student at secondary education institutions, vocational training programs, or undergraduate degree programs in the province of Granada, and being between 15 and 24 years of age.\n\nExclusion Criteria:\n\n* Exclusion criteria will include: lack of informed consent from the participant or their legal guardians in the case of minors, and the presence of barriers that prevent proper understanding of the questionnaires and activities to be carried out (e.g., language barriers, intellectual disability, etc.).","15 Years","24 Years",{"count":306,"type":22},202,[25],"Self-medication has traditionally been defined as the consumption of medicines, herbs, and home remedies on one's own initiative or on the advice of another person, without consulting a doctor. In Spain, the consumption of non-prescription drugs is quite widespread among young people, since more than half of them have used medications without a medical prescription in the last year.\n\nThis high prevalence of self-medication among Spanish youth seems to be driven by various factors that encourage this practice. These include the increase in over-the-counter medications, delays in obtaining appointments at health centers, the influence of common family self-care practices, and the population's greater knowledge of and interest in health-related issues.\n\nInappropriate use of medications constitutes a public health problem and can cause significant risks to users' health, such as adverse reactions, drug resistance, and complications in diagnosing diseases, since it can lead to the masking of symptoms, as well as an increase in morbidity.\n\nHowever, not all self-medication practices are harmful. Responsible self-medication refers to the use of over-the-counter medications (without a prescription) to treat common and mild symptoms (e.g., fever, mild pain, colds) for a reasonable period of time (two to three days, after which a doctor should be consulted if no improvement occurs). The benefits of responsible self-medication include convenience for the patient, reinforcement of personal autonomy through self-care, reduction of healthcare professionals' workload, and decreased costs to the healthcare system. In this regard, responsible self-medication not only provides individual and collective benefits but also promotes the development of personal autonomy, a key factor influencing young people's tendency to self-medicate. Attitudes toward autonomous medication use in young people are influenced by individual variables such as emotional regulation, family habits, peer influence, quality of life, and the use of other substances.\n\nGiven that these factors-greater access to medications, delays in healthcare access, family self-care practices, and individual psychosocial characteristics-appear to drive self-medication behaviors among youth, it is hypothesized that an educational intervention developed with the support of artificial intelligence, and focused on the responsible and safe use of medications, will improve young people's knowledge and attitudes toward self-medication. By targeting both knowledge and attitudes, the intervention aims to strengthen responsible practices while fostering autonomy and informed decision-making in medication use.",[310],"Self Medication",[312,313,314,310,315,316],"Health Literacy","Adolescent","Quality of Life","Artificial Intelligence","Education","2026-02-10",{"date":319,"type":41},"2026-02-11",{"date":321,"type":41},"2025-03-17",{"date":323,"type":22},"2026-12",{"name":47,"class":48},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100621388","respiratory-biofeedback-added-to-strengthening-training-in-patients-with-chronic-kidney-disease-100621388","NCT07369973","Respiratory Biofeedback Added to Strengthening Training in Patients With Chronic Kidney Disease","RESPI-REN","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Diagnosis of chronic kidney disease (CKD) at any stage\n* Clinically stable condition, with no acute medical events in the previous 4 weeks\n* Ability to understand and follow breathing and training instructions\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Acute respiratory infection or unstable pulmonary disease\n* Severe cognitive impairment or neurological condition limiting cooperation\n* Unstable cardiovascular disease or contraindications to respiratory muscle training\n* Recent thoracic or abdominal surgery (\\\u003C3 months)\n* Significant visual impairment that prevents proper use of the biofeedback device\n* Participation in another interventional clinical trial during the study period",{"count":333,"type":22},24,[25],"The goal of this clinical trial is to learn whether diaphragmatic biofeedback added to respiratory muscle training improves clinical and functional outcomes in adults with chronic kidney disease. It will also evaluate the feasibility and acceptability of this intervention.\n\nThe main questions it aims to answer are:\n\nIs diaphragmatic biofeedback added to respiratory muscle training acceptable and well tolerated in patients with chronic kidney disease? Does this intervention reduce respiratory symptoms and complications in this population? Does diaphragmatic biofeedback added to respiratory muscle training improve cardiorespiratory capacity and quality of life? Researchers will evaluate diaphragmatic biofeedback combined with respiratory muscle training and a placebo intervention based on conscious breathing to assess its effects.\n\nParticipants will:\n\n* Perform the assigned intervention three times per day for 6 weeks\n* Follow a structured respiratory muscle training program with diaphragmatic biofeedback\n* Be monitored for symptoms, respiratory complications, and perceived quality of life throughout the study",[337],"Chronic Kidney Disease (Stages 4 and 5)","2026-01-18",{"date":340,"type":41},"2026-01-27",{"date":342,"type":22},"2026-01",{"date":344,"type":22},"2026-08",{"name":47,"class":48},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":23,"phases":356,"briefSummary":357,"conditions":358,"keywords":362,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":371,"locationsCount":49},"100447451","photobiomodulation-therapy-plus-m-health-in-head-and-neck-cancer-patients-laxer-study-100447451","NCT05106608","Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study","Photobiomodulation Therapy With M-health Tool for the Management of Oral Health and Quality of Life in Head and Neck Cancer Patients: LAXER Study","LAXER","Patients will be included in the study if they meet the following inclusion criteria:\n\n* men or women aged 18 years or older and were diagnosed with HNC.\n* chronic xerostomia.\n* received RT in the parotid, submandibular and\u002For sublingual salivary glands.\n* grade 3 oral dryness according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE).\n* medical treatment completed and in complete remission.\n* received medical clearance for participation in this study.\n* at least one month passed since the end of RT to avoid the possible presence of oral mucositis and\u002For radiodermatitis, which limits adherence to treatment and maximum 36 months.\n* no history of drugs\u002Fdevices\u002Fproducts (pilocarpine, cevimeline, amifostine, oral devices, humidifiers, or herbs) to prevent or treat xerostomia prior to study inclusion or no change in their use (no change in type or dose) for two months prior to study inclusion.\n* and able to access mobile applications or living with someone who has this ability.\n\nThe exclusion criteria will be as follows:\n\n* patients with metastases.\n* a score \\\u003C60 on the Karnofsky Performance Status Scale.\n* contraindications to receiving PBM therapy (e.g., cardiac arrhythmias, pacemakers, photosensitivity, drugs with photosensitizing action, and pregnancy).\n* other comorbidities such as diabetes and polypharmacy.\n* and retraction of the declaration of consent.",{"count":355,"type":22},60,[25],"The Photobiomodulation therapy could have positive effects on quality of life and oral health in head and neck cancer survivors post-radiotherapy. The improvement in quality of life will be maintained after a follow-up period.",[359,360,361],"Head and Neck Cancer","Head and Neck Neoplasms","Xerostomia",[314,363,361,364,112],"Neoplasms","Low-Level Light Therapy","2025-12-30",{"date":367,"type":41},"2026-01-05",{"date":369,"type":41},"2022-07-13",{"date":323,"type":22},{"name":47,"class":48},{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":97,"minAge":18,"maxAge":19,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":382,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":49},"100412596","preventing-chemotherapy-induced-peripheral-neuropathy-using-presiona-exercise-program-100412596","NCT04652609","Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program","Prevention of Chemotherapy-induced Peripheral Neuropathy With Therapeutic Exercise and Blood Flow Restriction Using PRESIONA Program","PRESIONA","Inclusion Criteria:\n\n* 18 years or older\n* HER2+ breast cancer diagnosis\n* On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy)\n\nExclusion Criteria:\n\n* Previous diagnosis of cancer\n* Pregnant\n* Cardiac pathology\n* No symptoms or pathology that could be confused with neuropathy or related to diabetes\n* No recommendation from oncologist for therapeutic exercise practice",{"count":381,"type":22},25,[25],"The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.",[385],"Breast Neoplasm",[387,388,389,390],"Breast neoplasm","Breast cancer","Therapeutic exercise","Small Fiber Neuropathy","2025-11-15",{"date":393,"type":41},"2025-11-18",{"date":395,"type":41},"2021-01-01",{"date":397,"type":22},"2027-01-01",{"name":47,"class":48},{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":186,"sex":407,"minAge":18,"maxAge":408,"enrollmentInfo":409,"targetDuration":4,"studyType":23,"phases":411,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":49},"100601114","chronic-grape-extract-in-crosstraining-athletes-a-randomized-crossover-trial-100601114","NCT07106281","Chronic Grape Extract in Crosstraining Athletes: A Randomized Crossover Trial","Effect of Chronic Grape Extract Supplementation in Trained Cross-training Athletes: A Randomized, Triple-blinded, Placebo-Controlled Crossover Study","CROSSUVA","Inclusion Criteria:\n\n* Age: 18-35 years.\n* Body mass index: 18.5-30 kg\u002Fm2.\n* Ability to understand the instructions, objectives, and study protocol.\n* Minimum of 3 years of experience in crosstraining, with at least 6 hours of weekly training over the past 3 months.\n* Resident on the island of Tenerife.\n\nExclusion Criteria:\n\n* History of a significant adverse cardiovascular event, renal insufficiency, cirrhosis, eating disorder, weight control surgical intervention, or type 2 diabetes mellitus.\n* Any chronic pathology in which the intake of nutritional supplements, especially use of antioxidant supplements during the 4 weeks prior to the start of the study.\n* Any condition that, in the investigator's judgment, would impair the ability to participate in the study or represent a personal risk to the participant.\n* Use of medications that may affect the study results.\n* Unstable body weight for 3 months prior to the start of the study (\\> 4 kg loss or gain in weight).\n* Active tobacco abuse or illicit drug use, or history of treatment for alcohol abuse.\n* On a special diet or prescribed for other reasons (e.g., celiac disease).","MALE","35 Years",{"count":410,"type":22},30,[25],"The aim of this study is to investigate the effect of cronic GSE intake in crosstraining may have a favorable impact on biochemical markers, recovery, and performance.",[414],"Performance",[416,417,418,419,420],"grape seed extract","muscle damage","concurrent exercise","nutrition","recovery","2025-07-29",{"date":423,"type":41},"2025-08-06",{"date":425,"type":22},"2025-09-01",{"date":427,"type":22},"2026-01-31",{"name":47,"class":48},{"id":430,"slug":431,"hasResults":11,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":186,"sex":17,"minAge":18,"maxAge":242,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":441,"conditions":442,"keywords":445,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":49},"100595386","early-phase-1-topic-simvastatin-for-bone-regeneration-100595386","NCT07031778","Topic Simvastatin for Bone Regeneration","Efficacy of Topical Application of Simvastatin in Bone Regeneration","SM","Inclusion Criteria:\n\n* Anesthetic risk ASA I-II.\n* Patients with the adjacent tooth in the mouth (37 or 47).\n* Third molars with fully developed roots.\n* Mandibular third molars included or semi-included.\n* With indication for extraction.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Chronic smokers.\n* Patients with decompensated metabolic disease.\n* Patients with motor difficulties that prevent or hinder hygiene.\n* Patients who are using statins to treat hypercholesterolemia.\n* Patients under treatment with drugs that could affect the osseointegration process such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.\n* Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.",{"count":438,"type":22},90,[440],"EARLY_PHASE1","The goal of this clinical trial is to evaluate the efficacy of topical application of simvastatin in bone regeneration in the maxillae, in the reduction of dimensional bone changes, using mandibular third molar surgery as a model and assessing bone healing at 12 weeks. We will also compare the two forms of intralveolar topical administration currently used to assess which is the best form of administration. The main questions it aims to answer are:\n\n* Can the topical application of simvastatin, used as a preservation material, improve the variations with respect to bone dimensions and density that occur after tooth extraction.\n* Can topical application of SM improve soft tissue healing.\n* Does the topical application of SM produce changes with respect to postoperative variables of pain, inflammation or trismus.\n* What is the best vehicle for topical SM administration?\n\nFor this purpose, the investigators will randomly place 4 topical treatment options in the postextraction alveoli:\n\n* SM in gel form\n* collagen sponge impregnated with saline solution containing 10 mg of SM\n* collagen sponge with placebo gel. All patients will undergo postoperative CBCT, which will be repeated at 12 weeks.\n\nIn addition, inflammation, trismus and pain variables will be measured preoperatively, at 24 hours, 3 and 7 days.",[443,444],"Dimensional Changes","Bone Density",[446,447,448,449],"simvastatin","bone density","dimensional changes","cbct scan","2025-06-12",{"date":452,"type":41},"2025-06-22",{"date":454,"type":41},"2025-01-07",{"date":456,"type":22},"2025-12-31",{"name":47,"class":48},{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":186,"sex":17,"minAge":271,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":49},"100586521","evaluation-of-the-nutritional-status-of-omega-3-fatty-acids-and-the-possible-influences-of-dietary-patterns-and-different-socioeconomic-factors-in-a-spanish-population-over-60-years-of-age-100586521","NCT06916455","Evaluation of the Nutritional Status of Omega-3 Fatty Acids and the Possible Influences of Dietary Patterns and Different Socioeconomic Factors, in a Spanish Population Over 60 Years of Age","Evaluation of the Nutritional Status of Omega-3 Fatty Acids and the Possible Influences of Dietary Patterns and Different Socioeconomic Factors in a Spanish Population Over 60 Years of Age","OMEGAPRED","Inclusion Criteria:\n\n* Older than 60 years of age\n\nExclusion Criteria: Diseases that affect nutritional status\n\n* Gastrointestinal diseases that affect the absorption of nutrites\n* Cancer\n* Chronic kidney disease",{"count":467,"type":22},800,"The long-chain polyunsaturated fatty acids (PUFA) of the n-3 or omega-3 series and, in particular, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both derived from the essential fatty acid alpha-linolenic acid, are part of all cell membranes and from them derive numerous compounds such as prostaglandins, thromboxanes, leukotrienes, resolvins, protectins and maresins that play numerous biological roles, most notably in the control of body homeostasis, blood coagulation and inflammation. The omega-3 index is a biomarker that reflects the nutritional status of n-3 PUFA, as well as cardiometabolic risk and cardiovascular health. This index is determined as the sum of the percentages in weight of EPA and DHA over the total of fatty acids present in the erythrocyte membranes.\n\nPrevious studies carried out in Spain, such as ANIBES, indicate that in adults, and especially in those over 60 years of age, the intake of n-3 PUFA is well below the international recommendations, which is directly related to a low intake of fish, since both EPA and DHA are abundant in oily fish. However, in Spain, the nutritional status of omega-3 PUFA and their possible association with a higher prevalence of cardiometabolic risk is unknown, as well as the relationships with food intake and the cultural and socioeconomic status of the population. Therefore, the main objective of the present study is to evaluate the omega-3 index in the Spanish population over 60 years of age and to establish whether there are differences by sex, as well as in the different Spanish communities. In addition, we will study the possible associations between the omega-3 index and food intake, particularly of fish and omega-3 PUFA-rich supplements, as well as their possible associations with cardiometabolic risk indicators and cultural and socioeconomic conditions of the population.\n\nDetermination of the omega-3 index usually requires an invasive venous blood collection followed by processing for separation of erythrocytes and extraction and methylation of their membrane lipids followed by chromatographic analysis. But fatty acids can also be determined on whole blood using less invasive methods, such as obtaining drops of blood with a lancet and depositing them on chromatographic paper impregnated with an antioxidant (dried spots). All this makes sampling much easier, although the result of the omega-3 index has to be corrected because it is affected by the lipid composition present in the plasma. For this reason, this project aims to carry out a validation study between the results of the fatty acid profile obtained in erythrocytes and in whole blood in the Spanish population (medamediantedried spots). In short, the results obtained will be used to calculate regression lines that allow us to evaluate the omega-3 index in erythrocytes in the adult Spanish population from different regions of Spain by means of a minimally invasive methodology. For this purpose, 800 participants aged 60 years or more will be recruited from different regions of Spain, randomized by age and sex for each region; at least 100 of the total number of participants should be frequent consumers of omega-3 supplements; if this figure is not obtained, an active search will be carried out until this number is reached (booster). All of them will be interviewed to complete different questionnaires on cultural and socioeconomic status, history of metabolic disease and cardiovascular health, and questionnaires on frequency of consumption and food intake reminders as established by the European Union. With the help of health personnel from different pharmacies and in mutual agreement with the General Council of Pharmaceutical Associations of Spain, a whole blood sample will be taken by lancet, which will be used to quantify the omega-3 index. For the validation study it will be necessary to obtain whole venous blood extracted by venipuncture from a subsample of 200 participants. This sample will be processed and will be used to determine the fatty acid profile in whole blood and in erythrocytes, which will be related by means of multiple linear and bivariate regression models with the fatty acid profile obtained in the dried spots. Cardiometabolic risk markers will also be determined in these 200 subjects, which will be used to establish relationships with the calculated omega-3 status.",[470],"Fatty Acids, Omega-3",[472,473,474,475],"erythrocyte omega-3 fatty acids","population over 60 years of age","nutritional status","cardiovascular risk","2025-04-08",{"date":478,"type":41},"2025-04-11",{"date":480,"type":41},"2025-03-19",{"date":482,"type":22},"2026-12-31",{"name":47,"class":48},{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":492,"conditions":493,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":4},"100582534","comparison-of-three-types-of-sutures-in-oral-surgery-study-of-bacterial-colonization-tissue-reaction-and-clinical-characteristics-randomized-clinical-study-100582534","NCT06864559","Comparison of Three Types of Sutures in Oral Surgery. Study of Bacterial Colonization, Tissue Reaction and Clinical Characteristics: Randomized Clinical Study","Inclusion Criteria:\n\n* Patients with indication for extraction of a third lower molar retained in an unfavorable position that requires a bayonet incision in the surgical procedure.\n* Age: patients aged 18 years or older.\n* ASA I patients (Classification of the American Society of Anesthesiology, 1979): healthy patients who tolerate stress well, without systemic pathology, no anxiety and in whom a therapeutic modification is not necessary.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Smoking patients.",{"count":333,"type":22},[25],"Considering the wide variety of surgical sutures currently marketed in the field of Dentistry, it was decided to conduct a study comparing the microbial adhesion and antibacterial activity of three different types of sutures used in Oral Surgery (Silk, non-absorbable polyamide monofilament and non-absorbable expanded polytetrafluoroethylene).",[494,495,496,497],"Wound Healing Complication","Oral Surgery","Third Molar Extraction","Oral Infection","2025-03-03",{"date":500,"type":41},"2025-03-07",{"date":502,"type":22},"2025-03-01",{"date":504,"type":22},"2025-12-01",{"name":47,"class":48},{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":186,"sex":17,"minAge":241,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":517,"briefSummary":518,"conditions":519,"keywords":524,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":49},"100547952","the-energyco-study-100547952","NCT06414668","The ENERGYCO Study","ENERGY Expenditure of COmmuting to School","ENERGYCO","Inclusion Criteria:\n\n1. the school has a specific space for parking bicycles and allows for their parking\n2. the school does not have a specific school bus route\n3. the school has at least two lines per class\n4. at least eight students from the school will agree to participate in the study (i.e., presenting a signed parental consent).","17 Years",{"count":516,"type":22},300,[25],"The aims of this school-based cycling intervention called \"ENERGY Commuting to school\" (ENERGYCO) will be divided into two phases: Phase I will aim: 1) to design, test, and validate predictive equations for the objective quantification of the energy expenditure related to different modes of commuting to school (i.e., walking, cycling, motorized-vehicle); and 2) to quantify the energy expenditure of each mode of commuting to school using indirect calorimetry in adolescents; and Phase II will aim to evaluate the effect of a school-based cycling intervention on different health-related outcomes, such as energy expenditure, resting metabolic rate, basal metabolism, physical activity levels, body composition, muscle strength, cardiorespiratory fitness, blood pressure, physical literacy, motor competence, and psychosocial outcomes on Spanish adolescents.",[520,521,522,523],"Energy Expenditure","Physical Activity","Behavior","Body Composition",[525,526,527,528,529,530],"Resting metabolic rate","Energy expenditure","Physical activity","Body composition","Cycling","School","2024-12-03",{"date":533,"type":41},"2024-12-05",{"date":535,"type":41},"2023-02-01",{"date":537,"type":22},"2025-06-30",{"name":47,"class":48},{"id":540,"slug":541,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":23,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":49},"100568284","improving-health-status-in-covid-19-long-hauler-100568284","NCT06679218","Improving Health Status in COVID-19 Long-Hauler","Improving Health Status in COVID-19 Long-Hauler Through an Activity Coaching Programme: a Randomized Control Trial","Inclusion Criteria:\n\n* Patients of both sexes.\n* Agreed to participate.\n* Post COVID-19 condition patients meeting the WHO definition for this disease.\n* Sedentary patients according to the cut-off point of the International Physical Activity Questionnaire (IPAQ).\n\nExclusion Criteria:\n\n* Pulmonary, cardiac, neurological, vascular, or orthopaedic pathologies that could limit the execution of the evaluation and intervention.\n* Cognitive impairment that prevented them from understanding and answering the questionnaires.\n* Patients suffering from a reinfection with SARS-CoV-2.\n* Patients with a history of severe or critical COVID-19 disease severity.\n* Patients participating in other studies.",{"count":355,"type":22},[25],"This randomized clinical trial investigates the effects of a distance physical activity coaching program on the health of COVID-19 long-hauler. The study evaluates the impact of individualized coaching interventions to improve participants' physical activity and quality of life.",[550],"Post COVID-19 Condition","2024-11-06",{"date":553,"type":41},"2024-11-07",{"date":555,"type":22},"2024-11-11",{"date":557,"type":22},"2025-01-20",{"name":47,"class":48},{"id":560,"slug":561,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":186,"sex":17,"minAge":18,"maxAge":242,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":568,"briefSummary":569,"conditions":570,"keywords":571,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":578,"leadSponsor":579,"locationsCount":4},"100567121","early-phase-1-osteoimplant-and-bone-healing-100567121","NCT06664060","Osteoimplant and Bone Healing","Efficacy of Two Nutritional Supplements on Healing and Bone Density in the Jaws","Osteocic","Inclusion Criteria:\n\n* Patients presenting both lower third molars.\n* Adult patients between 18 and 40 years of age.\n* Anaesthetic risk ASA I-II (American Society of Anaesthesiologists classification) \\[14\\].\n* Absence of drug or food allergies that could compromise our study (e.g. egg).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Age not between 18-40 years.\n* Pregnant or breastfeeding women.\n* Presenting decompensated metabolic disease.\n* Poor periodontal status (≥10% plaque index and bleeding index).\n* Patients who have undergone radiotherapy in the last five years.\n* Patients who will not comply with the study guidelines.\n* Unsigned informed consent.\n* History of allergy to any study medication or related drugs (e.g. egg).\n* Patients with a history of renal colic.",{"count":355,"type":22},[440],"In view of the above and the possible improvements in terms of postoperative morbidity and tissue repair in oral surgery, this study is justified, the general objective of which would be:\n\n'To evaluate the efficacy of perioperative oral administration of two nutritional supplements based on vitamins and antioxidants (Osteoimplant Complex® and Osteoimplant®), using mandibular third molar surgery as a study model, assessing postoperative symptomatology and bone density'.\n\nThe null hypothesis of this study is: 1) the administration of the perioperative nutritional complex (Osteoimplant Complex® and Osteoimplant®) did not improve postoperative symptoms and 2) neither did it increase bone density after lower third molar extraction.",[443,444],[572,573,447,448],"vitamin d","vitamin c","2024-10-27",{"date":576,"type":41},"2024-10-29",{"date":454,"type":22},{"date":456,"type":22},{"name":47,"class":48},{"id":581,"slug":582,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":186,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":23,"phases":589,"briefSummary":590,"conditions":591,"keywords":594,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":4},"100566618","early-phase-1-osteoimplant-and-dental-implants-stability-100566618","NCT06657521","Osteoimplant and Dental Implants Stability","Influence of the Osteoimplant Vitamin Complex on the Stability of Dental Implants. Randomized Double-blind Clinical Trial.","OIMP","Inclusion Criteria:\n\n* Patients presenting with unitary or partial edentulism.\n\n  * Age: Between 18-75 years.\n  * Anaesthetic risk ASA I-II.\n  * Patients who do not abuse alcohol, drugs or chronic smoking (\\>10 cigarettes\u002Fday).\n  * Patients with adequate periodontal status (≤10% plaque index and bleeding index).\n  * Absence of drug allergies that could compromise our study.\n  * Absence of allergy to any of the components of Osteoimplant© and Osteimplant Complex©.\n  * Signed informed consent.\n\nExclusion Criteria:\n\n* Age not between 18-75 years old.\n* Pregnant or breastfeeding women.\n* Chronic smokers (\\>10 cigarettes\u002Fday).\n* Patients with decompensated metabolic disease.\n* Poor periodontal status (≥10% plaque index and bleeding index).\n* Patients allergic to any of the components of Osteoimplant© and Osteimplant Complex©.\n* Patients undergoing treatment with drugs that could affect the bone regeneration process, such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.\n* Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.\n* Patients with hypercalcaemia or a tendency to hypercalcification, taking vitamin D or calcium supplements.\n* Patients with a history of renal colic.\n* Patients who are not going to undergo nephrotic colic.",{"count":355,"type":22},[440],"Based on the scientific evidence, the relevance of this subject, we consider this study to be justified, the general or specific objective of which is as follows:\n\n'To evaluate the effect of the administration of Osteoimplant© and Osteoimplant Complex© as a food supplement in obtaining implant stability and in the healing of dental implant surgery'.\n\nAs secondary objectives, we will also evaluate the effect of Osteoimplant© and Osteoimplant Complex© on pain, postoperative inflammation and soft tissue healing.\n\nThe sample will consist of 60 patients. The sample will be randomly divided into 2 groups using a randomisation table generated by a statistical programme. For blinding, neither the patient nor the operator shall be aware of the group to which each patient belongs. To ensure blinding, medication will be delivered in sealed, opaque envelopes. Patients shall be assigned to one of the following groups:\n\n* Group I: 30 patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.\n* Group II: 30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.",[592,593],"Primary Stability of the Implants","Pain",[595,573,596,597,598,599],"Dental implant","vitamin D","stability","pain","inflamation","2024-10-23",{"date":602,"type":41},"2024-10-24",{"date":604,"type":22},"2025-01-01",{"date":456,"type":22},{"name":47,"class":48},{"id":608,"slug":609,"hasResults":11,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":11,"sex":97,"minAge":18,"maxAge":130,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":616,"briefSummary":617,"conditions":618,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":49},"100555024","effect-of-massage-and-hydrotherapy-to-improve-well-being-and-pain-perception-in-endometriosis-patients-100555024","NCT06506708","Effect of Massage and Hydrotherapy to Improve Well-being and Pain Perception in Endometriosis Patients","Effect of Massage and Hydrotherapy to Improve Well-being and Pain Perception in Women With Endometriosis Unresponsive to Conventional Treatment","Inclusion Criteria:\n\n* Pelvic pain during the last 6 months more or equal to 4 in a NRS scale.\n* Diagnosed with endometriosis (through surgery, magnetic resonance imaging or ultrasound imaging)\n* Premenopausal status\n* Be able to walk without assistance and to read and write enough\n* Be capable and willing to provide consent\n\nExclusion Criteria:\n\n* Acute or terminal illness\n* A recent fracture in any upper or lower extremity (\\\u003C3 months), disc herniation and any chronic disease or orthopaedic issues that would interfere with her ability to participate in this intervention program\n* Express unwillingness to complete the study requirements\n* Be involved in other rehabilitation program",{"count":615,"type":22},44,[25],"The objective is to analyze the short-term effect of a comprehensive HAMMAM experience combining therapeutic hydrotherapy, aromatherapy, music therapy, and Swedish massage on objective parameters and patient-reported outcomes related to well-being generation and pain reduction in women with endometriosis-related chronic pelvic pain.",[619,620],"Endometriosis","Chronic Pelvic Pain Syndrome","2024-07-16",{"date":623,"type":41},"2024-07-17",{"date":625,"type":41},"2023-05-01",{"date":627,"type":22},"2024-07-31",{"name":47,"class":48},""]